Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00294346 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder
A Phase 2 study of Social Phobia, sponsored by Avera Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 15
- Study locations
NCT00294346 is a Phase 2 study of Social Phobia that has completed, run by Avera Pharmaceuticals. The registered enrollment target is 180 participants, above the 128-participant average among 8 other Social Phobia trials with a reported enrollment target (41% higher). The trial reports 15 study locations across 10 states.
The verdict
NCT00294346, a Phase 2 study of Social Phobia, has completed, sponsored by Avera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to look at the safety and effectiveness of an investigational drug (AV608) when used in subjects who have Social Anxiety Disorder. AV608 is an NK-1 receptor antagonist that exhibits central nervous system activity after oral administration. The study will compare AV608 to placebo (a medically inactive substance) to see if AV608 helps the symptoms of Social Anxiety Disorder. Eligible subjects will be assigned by chance to take either AV608 or placebo for 12 weeks. During the study, subjects will be asked about their overall health and mood and their Social Anxiety Disorder.
Conditions Studied
Interventions
- DRUG AV608
Study Locations (15)
Florida
- CNS Healthcare - Jacksonville
- Comprehensive Neuroscience, Inc. - St. Petersburg
- University of South Florida - Tampa
California
- Southwestern Research, Inc. - Beverly Hills
- Affiliated Research Institute - San Diego
Maryland
- DuPont Clinical Research, Inc. - Rockville
- Capital Clinical Research Associates - Rockville
Texas
- Claghorn-Lesem Research Clinic, LLP - Bellaire
- Croft Group Research Center - San Antonio
Alabama
- Birmingham Research Group, Inc. - Birmingham
Arizona
- Pivotal Research Centers - Mesa
New York
- Medical Research Network, LLC - New York
Ohio
- Hartford Research - Cincinnatti
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2006-02 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00294346
The ClinicalTrials.gov registry entry for NCT00294346 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 128-participant average among 8 other Social Phobia trials with a reported enrollment target (41% higher). The listed sponsor is Avera Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Social Phobia appearing as the primary indexed condition, and to 1 intervention - of which AV608 is the first listed.
NCT00294346 reports 15 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT00294346 about?
NCT00294346 is a clinical study titled "Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder". The purpose of this study is to look at the safety and effectiveness of an investigational drug (AV608) when used in subjects who have Social Anxiety Disorder. AV608 is an NK-1 receptor antagonist that exhibits central nervous system activity after oral administration. The study will compare AV608 t...
What is the current status of trial NCT00294346?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2006-02. Estimated completion is 2006-12.
What conditions does trial NCT00294346 study?
This clinical trial studies the following conditions: Social Phobia.
What interventions are being tested in trial NCT00294346?
The interventions under investigation include: AV608 (DRUG).
Who is sponsoring clinical trial NCT00294346?
This trial is sponsored by Avera Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00294346 being conducted?
This trial has 15 study locations across Alabama, Arizona, California, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Social Phobia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder
COMPLETED · Phase 2
-
Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders
COMPLETED · Phase 2
-
Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia
COMPLETED · Phase 2
-
Mindful Self-Compassion for Anxiety Disorders and Depression
RECRUITING · NA
-
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
ACTIVE NOT RECRUITING · NA
-
Psychotherapy for Anxiety in Children With Autism Spectrum Disorder
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.